IDX719, HCV NS5A Inhibitor, Demonstrates Pan-Genotypic Activity after Three Days of Monotherapy in Genotype 1, 2, 3 or 4 HCV-Infected Subjects......http://www.natap.org/2013/HCV/013113_03.htm
Idenix has 2 nucleotides being studied separately but they could be studied in combination.
Here are select slides from yesterday's Idenix investor conference call:
